[HTML][HTML] Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma
M Kirschbaum, P Frankel, L Popplewell… - Journal of clinical …, 2011 - ncbi.nlm.nih.gov
M Kirschbaum, P Frankel, L Popplewell, J Zain, M Delioukina, V Pullarkat, D Matsuoka…
Journal of clinical oncology, 2011•ncbi.nlm.nih.govPhase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's
Lymphoma and Mantle Cell Lymphoma - PMC Back to Top Skip to main content NIH NLM Logo
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC
Full-Text Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol
PMC3083875 Other Formats PubReader PDF (133K) Actions Cite Collections Share Permalink
Copy RESOURCES Similar articles Cited by other articles Links to NCBI Databases Journal …
Lymphoma and Mantle Cell Lymphoma - PMC Back to Top Skip to main content NIH NLM Logo
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC
Full-Text Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol
PMC3083875 Other Formats PubReader PDF (133K) Actions Cite Collections Share Permalink
Copy RESOURCES Similar articles Cited by other articles Links to NCBI Databases Journal …
Abstract
Purpose
We performed a phase II study of oral vorinostat, a histone and protein deacetylase inhibitor, to examine its efficacy and tolerability in patients with relapsed/refractory indolent lymphoma.
ncbi.nlm.nih.gov
